Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8023997 | 0.80 | SMN1; SMN2 (0.37) | SMN1; SMN2CA14 | |
| SCHEMBL8023996 | 0.80 | SMN1; SMN2 (0.37) | SMN1; SMN2CA14 | |
| SCHEMBL31324711 | 0.76 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14 | |
| SCHEMBL31324723 | 0.76 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14 | |
| SCHEMBL7276278 | 0.76 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14 | |
| SCHEMBL13266324 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2CA14 | |
| SCHEMBL590895 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2CA14 | |
| SCHEMBL320222 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2CA14 | |
| SCHEMBL6064611 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2CA14 | |
| SCHEMBL590894 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139593-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS AND COMPOUNDS FOR SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139593-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS AND COMPOUNDS FOR SAME | GPX4, TXNRD2, TXN2 | SMN1; SMN2 173/4885CA14 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.